Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2022)

Historic Non-Current Debt for RedHill Biopharma (RDHL) over the last 3 years, with Q4 2022 value amounting to $115.2 million.

  • RedHill Biopharma's Non-Current Debt rose 3778.52% to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year increase of 3778.52%. This contributed to the annual value of $115.2 million for FY2022, which is 3778.52% up from last year.
  • As of Q4 2022, RedHill Biopharma's Non-Current Debt stood at $115.2 million, which was up 3778.52% from $113.9 million recorded in Q3 2022.
  • RedHill Biopharma's Non-Current Debt's 5-year high stood at $115.2 million during Q4 2022, with a 5-year trough of $78.2 million in Q1 2020.
  • Over the past 3 years, RedHill Biopharma's median Non-Current Debt value was $83.3 million (recorded in 2021), while the average stood at $87.7 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 274.49% in 2021, then soared by 3778.52% in 2022.
  • Quarter analysis of 3 years shows RedHill Biopharma's Non-Current Debt stood at $81.4 million in 2020, then rose by 2.74% to $83.6 million in 2021, then surged by 37.79% to $115.2 million in 2022.
  • Its Non-Current Debt was $115.2 million in Q4 2022, compared to $113.9 million in Q3 2022 and $85.5 million in Q2 2022.